# PDS Biotechnology Corp (PDSB) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_94e2652f6a4c86f511f5 · retrieved 2026-08-11T16:11:13.363Z

## Overview
PDS Biotechnology Corporation is a clinical-stage immunotherapy company developing a pipeline of targeted cancer and infectious disease immunotherapies based on its Versamune® T cell activator and Versamune® in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, and the Infectimune® T cell-activator for infectious diseases.

On April 30, 2026, PDS Biotechnology Corporation entered into a Securities Purchase Agreement with YA II PN, LTD., a Cayman Islands exempt limited company. On June 15, 2026 (the Closing Date), the Company issued a promissory note with an aggregate principal amount of $6,000,000 and a warrant to purchase up to 2,158,274 shares of Common Stock at an exercise price of $1.1824 per share, for a total purchase price of $5,760,000 (reflecting a 4% original issue discount). The Promissory Note has a maturity date of twelve months from the Closing Date and bears interest at 10% per annum, payable monthly beginning on the 60-day anniversary of the Closing Date. The Promissory Note is convertible into shares of Common Stock at the option of the Selling Stockholder upon the occurrence and during the continuance of a payment event of default, at a conversion price of 95% of the lowest daily VWAP during the five consecutive trading days prior to conversion or 92% of the closing price on the trading day immediately prior to conversion, but in no event lower than 20% of the Minimum Price. The Warrant is exercisable beginning on the six-month anniversary of the Closing Date and expires five years after the Closing Date.

## Terms
- Counterparty: YA II PN, LTD. · Deal value: $5.8M · Consideration: mixed · Stake: 19.23% · Price/share: $1.1824

## Key dates
- Announced 2026-07-21 · Expiry 2031-06-15

## Timeline
- 2026-07-21 · 424B4 (0001140361-26-029135): 424B4 - PDS Biotechnology Corp — *PDS Biotechnology Corporation is a clinical-stage immunotherapy company developing a pipeline of targeted cancer and infectious disease immunotherapies based on its Versamune® T cell activator and Versamune® in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, and the Infectimune® T cell-activator for infectious diseases.* On April 30, 2026, PDS Biotechnology Corporation entered into a Securities Purchase Agreement with YA II PN, LTD., a Cayman Islands exempt limited company. On June 15, 2026 (the Closing Date), the Company issued a promissory note with an aggregate principal amount of $6,000,000 and a warrant to purchase up to 2,158,274 shares of Common Stock at an exercise price of $1.1824 per share, for a total purchase price of $5,760,000 (reflecting a 4% original issue discount). The Promissory Note has a maturity date of twelve months from the Closing Date and bears interest at 10% per annum, payable monthly beginning on the 60-day anniversary of the Closing Date. The Promissory Note is convertible into shares of Common Stock at the option of the Selling Stockholder upon the occurrence and during the continuance of a payment event of default, at a conversion price of 95% of the lowest daily VWAP during the five consecutive trading days prior to conversion or 92% of the closing price on the trading day immediately prior to conversion, but in no event lower than 20% of the Minimum Price. The Warrant is exercisable beginning on the six-month anniversary of the Closing Date and expires five years after the Closing Date.
  https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-029135.txt

## Citations
- 0001140361-26-029135 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126029135